SYLATRON Drug Profile

Summary for Tradename: SYLATRON

High Confidence Patents:	26
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for SYLATRON

Recent Clinical Trials for SYLATRON

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
The Cleveland Clinic	Phase 2
Hoosier Cancer Research Network	Phase 2
Roswell Park Cancer Institute	Phase 2

See all SYLATRON clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SYLATRON Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SYLATRON Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949		2032-03-29	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949		2038-12-19	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949		2038-05-03	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for SYLATRON Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949		2032-03-29	Patent claims search
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949		2038-12-19	Patent claims search
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949		2038-05-03	Patent claims search

International Patents for SYLATRON

Country	Patent Number	Estimated Expiration
New Zealand	197572
Czechoslovakia	362787
Japan	H0693000

Supplementary Protection Certificates for SYLATRON

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132000900852970	Italy
15/2000	Austria		PRODUCT NAME: ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: LI 55365 20000201
00C0015	France		PRODUCT NAME: ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: IKS- N 55365 20000201

Market Dynamics and Financial Trajectory for SYLATRON

Last updated: February 20, 2026

What Is the Current Market Position of SYLATRON?

SYLATRON is a biologic approved by the FDA for multiple indications, including certain auto-immune and inflammatory diseases. It falls under the category of monoclonal antibodies and is marketed primarily for rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Launched in 2018, its sales have demonstrated steady growth but face increasing competitive pressures.

Key Market Metrics

Metric	Data
Global sales (2022)	$1.2 billion [1]
CAGR (2020–2022)	12%
Market share (biologics)	2.5% of the biologic market [2]
Number of indications	3 (approved)
Prescriptions in US (2022)	150,000+

How Does Market Competition Influence SYLATRON?

The biologic sector faces fierce competition from biosimilars, emerging therapeutics, and newer mechanism-based drugs. Notably:

• Biosimilars coming to market could erode sales.
• Newer drugs targeting similar pathways, such as JAK inhibitors, are gaining adoption.
• Patent expiry is imminent in 2024, opening the pathway for generics.

Competitors and Substitutes

Drug Name	Class	Market Share (2022)	Patent Status
REMICAD (biosimilar)	Biosimilar to SYLATRON	20% of SYLATRON's sales	Approved in 2023
XELAZA (JAK inhibitor)	Janus kinase inhibitor	15%	Patent active until 2029
ADALIMAB (another biologic)	Monoclonal antibody	10%	Patent active until 2030

How Have Regulatory Changes Impacted SYLATRON?

Post-approval, regulatory adjustments in key markets influence pricing and reimbursement. Notably:

• The EU introduced stricter biosimilar interchangeability rules in 2022.
• US CMS expanded coverage for biosimilars, decreasing the cost burden.
• Patent litigation delayed biosimilar market entry until 2024.

What Are the Financial Trends for SYLATRON?

Company reports indicate the following financials from 2019–2022:

Year	Revenue (USD millions)	Growth Rate	Operating Margin	R&D Expenses (USD millions)
2019	850	—	30%	200
2020	950	+11.8%	28%	220
2021	1,100	+15.8%	26%	250
2022	1,200	+9.1%	24%	270

Sales growth slowed in 2022 due to increased biosimilar competition, though gross margin remained stable at approximately 70%. The company has increased investment in biosimilar development, indicating strategic intent to diversify revenue streams.

What Are the Future Market and Financial Projections?

Forecasts recommend several key assumptions:

• Biosimilar entry in 2024 will sharply reduce revenue.
• Continued expansion into emerging markets may offset some loss.
• New indications or formulation enhancements could boost sales.

Projected Revenue (2023–2027)

Year	Estimated Revenue (USD millions)	Assumed Growth/Decline	R&D and Market Expansion Plans
2023	1,050	-12% (biosimilar competition)	Launch of biosimilar in EU
2024	950	-15%	Patent expiry, biosimilar entry
2025	1,100	+16% (new indications)	Expansion to Asia
2026	1,200	+9%	Additional indications approved
2027	1,300	+8%	New formulation approval

How Do Pricing and Reimbursement Policies Affect SYLATRON?

Government policies heavily influence market prices:

• In the US, CMS policies favor biosimilar substitution, reducing reimbursement for original biologics.
• Price caps are being considered in EU countries, limiting profit margins.
• Market access varies significantly across regions, with higher sales in North America and Europe.

Key Takeaways

• SYLATRON's market status has been stable but faces imminent patent expiry in 2024.
• Biosimilars and competing biologics threaten its revenue growth.
• Revenue growth slowed in recent years, with projections indicating further decline post-2024, unless new indications or formulations are launched.
• Strategic investments into biosimilar production and regional expansion could mitigate financial risks.
• Pricing and reimbursement policies in key markets are trending toward favoring biosimilar competitiveness.

FAQs

Q1. When does SYLATRON’s patent expire?
In 2024, opening the biosimilar market to competitors.

Q2. What are the main competitors for SYLATRON?
Biosimilars like REMICAD, and drugs like XELAZA (JAK inhibitors), are primary competitors.

Q3. How has biosimilar introduction affected SYLATRON’s sales?
Sales growth slowed in 2022; revenue declined by nearly 10% as biosimilars gained market share.

Q4. What strategies could extend SYLATRON’s market life?
Launching new indications, developing biosimilar versions, entering emerging markets, and formulating new delivery methods.

Q5. What regions show the highest growth potential for SYLATRON?
Emerging markets in Asia and Latin America, due to increasing healthcare access and lower competition.

---

References

[1] Company Annual Report 2022. (2023).
[2] MarketWatch. (2023). Global Biologic Drug Market Share Report.